Allain H., Bentue-Ferrer D., Tribut O., Gauthier S., Michel B. F., Drieu-La Rochelle C. (2003). Alzheimer's disease: the pharmacological pathway, Fundam Clin Pharmacol , 17 (4 ), 419-28.

Desrosiers R. R., Bertrand Y., Nguyen Q. T., Demeule M., Gabathuler R., Kennard M. L., Gauthier S., Beliveau R. (2003). Expression of melanotransferrin isoforms in human serum: relevance to Alzheimer's disease, Biochem J , 374 (Pt 2 ), 463-71.

Feldman H., Gauthier S., Hecker J., Vellas B., Emir B., Mastey V., Subbiah P., The Donepezil MSAD Study Investigators Group (2003). Efficacy of donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimer`s disease, and the impact on caregiver burden, J Am Geriatr Soc , 51 , 737-744.

Feldman H., Levy A. R., Hsiung G. Y., Peters K. R., Donald A., Black S. E., Bouchard R. W., Gauthier S., Guzman D. A., Hogan D. B., Kertesz A., Rockwood K. (2003). A Canadian cohort study of cognitive impairment and related dementias (ACCORD): study methods and baseline results, Neuroepidemiology , 22 (5 ), 265-74.

Gauthier S. (2003). Clinical aspects of Alzheimer's disease . In Mulligan R., Van de Linden M., Juillerat A.C. & Mulligan R. (Eds.) , Clinical management of early Alzheimer's disease (pp. 21-34). Lawrence Erlbaum Associates, Inc..

Gauthier S. (2003). Management of later stages of Alzheimer’s disease . In Vellas B., Winblad B., Grundman M., Fitten L. J., Feldman H., Giacobini E., Kurz A. & Vellas B. (Eds.) , Research and Practice in Alzheimer's Disease (pp. 146-149). F.A. Davis.

Gauthier S., Emre M., Farlow M. R., Bullock R., Grossberg G. T., Potkin S. G. (2003). Strategies for continued successful treatment of Alzheimer's disease: switching cholinesterase inhibitors, Curr Med Res Opin , 19 (8 ), 707-14.

Gauthier S., Joober R., Mottron L., Laurent S. B., Fuchs M., De Kimpe V., Rouleau G. A. (2003). Mutation screening of FOXP2 in individuals diagnosed with autistic disorder, Am J Med Genet , 118A (2 ), 172-5.

Gauthier S., Rockwood K. (2003). Does vascular MCI progress at a different rate than Amnestic MCI?, Int Psychogeriatr , 15 (suppl. 1) , 257-259.

Law A., Gauthier S., Quirion R. (2003). Alteration of nitric oxide synthase activity in young and aged apolipoprotein E-deficient mice, Neurobiol Aging , 24 (1 ), 187-90.

Marcusson J., Bullock R., Gauthier S., Kurz A., Schwalen S. (2003). Galantamine demonstrates efficacy and safety in elderly patients with Alzheimer disease, Alzheimer Dis Assoc Disord , 17 Suppl 3 , S86-91.

O'Brien J. T., Erkinjuntti T., Reisberg B., Roman G., Sawada T., Pantoni L., Bowler J. V., Ballard C., DeCarli C., Gorelick P. B., Rockwood K., Burns A., Gauthier S., DeKosky S. T. (2003). Vascular cognitive impairment, Lancet Neurol , 2 (2 ), 89-98.

Rockwood K., Davis H., MacKnight C., Vandorpe R., Gauthier S., Guzman A., Montgomery P., Black S. E., Hogan D. B., Kertesz A., Bouchard R. W., Feldman H. (2003). The Consortium to Investigate Vascular Impairment of Cognition: methods and first findings, Can J Neurol Sci , 30 (3 ), 237-43.